JP2020534858A - 短鎖脂肪酸生成腸内細菌群集の変化を用いたアルコール性肝疾患の診断および治療用組成物 - Google Patents
短鎖脂肪酸生成腸内細菌群集の変化を用いたアルコール性肝疾患の診断および治療用組成物 Download PDFInfo
- Publication number
- JP2020534858A JP2020534858A JP2020518722A JP2020518722A JP2020534858A JP 2020534858 A JP2020534858 A JP 2020534858A JP 2020518722 A JP2020518722 A JP 2020518722A JP 2020518722 A JP2020518722 A JP 2020518722A JP 2020534858 A JP2020534858 A JP 2020534858A
- Authority
- JP
- Japan
- Prior art keywords
- strain
- rosebria
- fatty liver
- alcoholic fatty
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims description 5
- 150000004666 short chain fatty acids Chemical class 0.000 title description 10
- 238000003745 diagnosis Methods 0.000 title description 6
- 208000022309 Alcoholic Liver disease Diseases 0.000 title description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims abstract description 100
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 94
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims abstract description 89
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims abstract description 89
- 239000006041 probiotic Substances 0.000 claims abstract description 17
- 235000018291 probiotics Nutrition 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 230000000968 intestinal effect Effects 0.000 claims description 82
- 230000014509 gene expression Effects 0.000 claims description 62
- 230000001965 increasing effect Effects 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- 210000004185 liver Anatomy 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 27
- 210000003495 flagella Anatomy 0.000 claims description 24
- 210000002919 epithelial cell Anatomy 0.000 claims description 21
- 230000035699 permeability Effects 0.000 claims description 20
- 108090000304 Occludin Proteins 0.000 claims description 17
- 210000001578 tight junction Anatomy 0.000 claims description 17
- 102000003940 Occludin Human genes 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 210000000936 intestine Anatomy 0.000 claims description 14
- 230000000529 probiotic effect Effects 0.000 claims description 14
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 11
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 11
- 239000002207 metabolite Substances 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 8
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 7
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 7
- 108010045374 CD36 Antigens Proteins 0.000 claims description 6
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000002440 hepatic effect Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 238000010171 animal model Methods 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 102000049320 CD36 Human genes 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 6
- 238000010586 diagram Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 120
- 239000013641 positive control Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 29
- 239000002158 endotoxin Substances 0.000 description 26
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 26
- 210000004379 membrane Anatomy 0.000 description 26
- 229920006008 lipopolysaccharide Polymers 0.000 description 25
- 239000013642 negative control Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 15
- 244000005700 microbiome Species 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 238000005728 strengthening Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108020004465 16S ribosomal RNA Proteins 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 206010067125 Liver injury Diseases 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000000713 mesentery Anatomy 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100034263 Mucin-2 Human genes 0.000 description 5
- 210000004534 cecum Anatomy 0.000 description 5
- 238000010219 correlation analysis Methods 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 241000702460 Akkermansia Species 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 4
- 102000053028 CD36 Antigens Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000192031 Ruminococcus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000003012 network analysis Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 3
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000605861 Prevotella Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000007473 univariate analysis Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 2
- OVBFMEVBMNZIBR-UHFFFAOYSA-N 2-methylvaleric acid Chemical compound CCCC(C)C(O)=O OVBFMEVBMNZIBR-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 230000008944 intestinal immunity Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- -1 maltose and sucrose Chemical compound 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000778935 Akkermansia muciniphila ATCC BAA-835 Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001202853 Blautia Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 208000020060 Increased inflammatory response Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000043362 Megamonas Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000158147 Sator Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079866 intestinal antibiotic Drugs 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/206—Bacterial extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
アルコールを摂取させた対照群の腸内に存在する請求項1によるアルコール性脂肪肝症状緩和活性を有するロゼブリア属菌株の量を測定する第2段階;および
前記第1段階および第2段階で測定したロゼブリア属菌株の量を比較する第3段階を含むアルコール性脂肪肝診断に関する情報を提供する方法を提供することを目的とする。
本発明によるアルコール性脂肪肝改善活性を有するロゼブリア属菌株は、例えば、アルコール摂取量による腸内菌叢分析結果、アルコール摂取量が少ない正常グループでロゼブリア属菌株が連関性を示し、前記連関性を示したロゼブリア属菌株を選択して本発明によるアルコール性脂肪肝改善活性を有するロゼブリア属菌株として採択した。本発明によるロゼブリア属菌株は、腸内菌叢に由来したものであってもよい。
(1)上皮細胞間密着結合(tight junction)を強化、上皮細胞膜の上皮電気抵抗を増加、Zo−1およびOccludin遺伝子の発現量増加、またはMUC2遺伝子の発現量増加、
(2)アルコール性脂肪肝の発生原因物質、例えば、血中リポ多糖類(LPS)の濃度減少、
(3)肝損傷の改善、血中ALT濃度減少、血中AST濃度減少、肝の中性脂肪減少、生体内腸壁透過度実験でFITC投与時血中FITC蛍光発現減少、またはOil Red O染色結果、肝の脂肪量減少、
(4)脂肪肝誘発遺伝子の発現減少、またはPPAR−rおよびCD36遺伝子の発現量減少、
(5)肝損傷症状の改善または治療、CXCL2およびCXCL5遺伝子の発現量減少、
(6)肝での炎症反応減少、またはTNF−αおよびIL−1β遺伝子の発現量減少。
(7)腸内微生物菌叢回復および多様性増加、
(8)DNA回復および代謝と関連した腸内微生物菌叢機能性増加。
韓国人双子コホートで410人の一卵性、二卵性双子とその家族らを対象にして大便試料を採取して−80℃に冷凍保管した。冷凍保管された試料を実験室に移してQIAamp FAST DNA stool mini kit(Qiagen)を用いてバクテリアゲノムDNAを抽出した。本コホートではアルコール摂取量(g/day)およびアルコール摂取習慣アンケート調査結果であるAUDITスコア臨床指標を活用して、AUDITスコアによるゾーンI(0−7点、正常グループ)、ゾーンII(8−15点)、ゾーンIII(16−40点、アルコール摂取量が多いグループ)に分けて分析した。本コホートのアルコール摂取量(g/day)およびAUDITスコアの相関関係分析結果およびグループによる年齢、性別、C反応性蛋白(hsCRP)臨床指標情報を図1に示した。
実施例1で抽出されたDNAを、バクテリアの16S rRNA遺伝子のV4領域をターゲットとする下記表1の515F/806Rプライマー(配列番号1および2)を用いて増幅し、Illumina社のMiSeq機器を用いて塩基配列データを生成した。生成された大容量塩基配列をQIIME pipelineを使用して分析し、腸内細菌の全体遺伝情報を確認して腸内菌叢の構造を把握後、アルコール摂取量指標との連関性を観察した。
年齢、性別、家族歴を補正して混乱変数を制御することができるMaAsLin(Multivariate analysis by linear models)ソフトウェアを用いて、多変量分析を通じてアルコール摂取量による腸内菌叢の変化およびこれによる腸の健康を特定することができる腸内バクテリアを糾明した。MaAsLinソフトウェアを使用して年齢、性別、双子と家族関係をランダム変数に、アルコール摂取グループを補正変数に指定後、健康要因と腸内菌叢の連関性をOTU(Operational Taxonomic Units、16S基盤生物情報学的細菌分類単位)および分類群(taxon)に分けて分析し、その結果を図3および図4に示した。
アルコール摂取量が多いグループと正常グループで腸内菌叢の発生パターンを把握するためにcytoscapeソフトウェアを用いてネットワーク分析を実施した。
韓国人双子コホートの一部である307個の糞便試料で腸内菌叢由来代謝産物である短鎖脂肪酸(short chain fatty acid)分析を実施した。同量の糞便試料を滅菌された3次蒸留水に溶かし、95%(v/v)硫酸を使用して酸性化させた後、遠心分離して上層液を回収した。
健康な韓国人の腸内菌叢でロゼブリア・インテスティナリス(Roseburia intestinalis)菌株を分離した。具体的に、腸内菌叢分離用試料を健康な一般人成人から提供を受けて、糞便試料から菌株を分離、同定した(IRB承認番号:1602/001−001)。
腸上皮細胞間膜強化特性(tight junction強化特性)試験のための動物細胞としてCaco−2細胞株を米国細胞株銀行(ATCC)から分譲を受けて使用した。Caco−2細胞株はヒト大腸由来結腸直腸癌adenocarcinoma細胞であって、形態は上皮細胞である。
8−1:ロゼブリア属菌株の鞭毛抽出
ロゼブリア属菌株の鞭毛を抽出するために、以下のように実施した。
実施例8−1で得られたタンパク質抽出物をPAGE gel、およびLTQ−Orbitrap質量分析器を用いて分析した。
ロゼブリア属菌株由来鞭毛に腸上皮細胞間膜密着結合強化特性があるのを確認するために、以下のように実施した。
単一菌株投与による腸内菌叢の変化とアルコール性脂肪肝の因果関係を糾明するために動物実験を実施した。
10−1:定量分析
実施例9の実験終了時、マウスの血液を収得して血中アラニンアミノ伝達酵素(ALT)、バクテリアのグラム陰性菌の細胞壁を構成するリポ多糖類(LPS、lipopolysaccharide)、およびアスパラギン酸アミノ基転移酵素(AST)を測定した。また、肝での中性脂肪(Triglycerides、TG)を測定し、実験終了直前にfluorescein isothiocyanate(FITC)蛍光が付けられたデキストラン(4kDa)を経口投与(60mg/100g body weight)して4時間後に血液を収得して血中内蛍光を測定するin vivo permeability(FITC)を実施した。その結果を図11に示した。
組織病理学的観察のために肝組織を10%ホルマリンで固定させた後、ヘマトキシリン&エオシン(H&E、Hematoxylin&Eosin)染色を実施した結果を図12に示し、肝組織の損傷尺度であるOil Red O染色を実施した結果およびImageJ softwareを使用してこれを定量した結果を図13aおよび図13bに示した。
組織の遺伝子発現量分析のために肝組織のRNAをRNeasy Lipid tissue mini kit(Qiagen)を使用して抽出し、腸組織のRNAをeasy−spin total RNA extraction kit(Intron)を使用して抽出した。これをhigh capacity RNA−to−cDNA kit(Applied biosystems)を使用してcDNAとして合成させた後、roter−gene SYBR green PCR kit(Qiagen)を使用して遺伝子発現量を分析した結果を図14(肝組織)、および図15a(腸組織)に示した。
腸組織のタンパク質発現量分析のために腸組織のタンパク質をprotease inhibitor cocktailが添加されたRIPAバッファーに均質化して抽出後、BCA protein assay kit(Thermo Fisher Scientific)を使用して定量した。10% β−mercaptoethanolが含まれているLaemmli sample loading buffer(Bio−Rad)を添加して10分間85°Cで沸かした後、10% SDS−PAGE gelを実施した。その後、membraneは5%BSAが添加されたTBSTで1時間blocking後、1次、2次抗体を付けて反応を行った。反応の強さはGeneTools(Syngene)を通じて定量した。
実施例9の実験終了時、マウスの盲腸を収得して−81℃に冷凍保管し、試料を実験室に移してQIAamp FAST DNA stool mini kit(Qiagen)を用いてバクテリアgenomic DNAを抽出した。抽出されたDNAを、バクテリアの16S rRNA遺伝子のV3−4領域をターゲットとする下記表5のプライマー(配列番号28および29)を用いて増幅し、index PCRを行った後、Illumina社のMiSeq機器を用いて塩基配列データを生成した。生成された大容量塩基配列をQIIME pipelineを使用して分析し、腸内細菌の全体遺伝情報を確認して腸内菌叢の構造を把握後、グループによる単変量分析(LefSE)を実施した。
Claims (15)
- アルコール性脂肪肝の予防または改善活性を有する、ロゼブリア(Roseburia)属菌株。
- 前記ロゼブリア属菌株は、上皮細胞間密着結合(tight junction)の増加、アルコール性脂肪肝原因物質の減少、および腸壁透過性の減少からなる群より選択される1以上の特性を有するものである、請求項1に記載のロゼブリア属菌株。
- 前記上皮細胞間密着結合の増加特性は、前記ロゼブリア属菌株の鞭毛によるものである、請求項2に記載のロゼブリア属菌株。
- 前記上皮細胞間密着結合の増加は、アルコール性脂肪肝誘導動物モデルで、前記ロゼブリア属菌株で処置していない対照群に比べて、前記ロゼブリア属菌株処置群で上皮細胞膜の上皮電気抵抗増加、オクルディン(Occludin)遺伝子の発現量増加、またはMUC2遺伝子の発現量増加によるものである、請求項2に記載のロゼブリア属菌株。
- 前記ロゼブリア属菌株は、CXCL2遺伝子、CXCL5遺伝子、TNF−α遺伝子、およびIL−1β遺伝子からなる群より選択される1種以上の肝炎症性サイトカインの発現量減少特性を有する、請求項1に記載のロゼブリア属菌株。
- 前記アルコール性脂肪肝の予防または改善は、前記ロゼブリア属菌株の摂取による血中ALT濃度の減少、血中AST濃度の減少、肝の中性脂肪の減少、肝の脂肪量減少、および肝の脂肪合成関連遺伝子の発現減少からなる群より選択される1種以上の肝機能指標が改善されることである、請求項1に記載のロゼブリア属菌株。
- 前記肝の脂肪合成関連遺伝子は、PPAR−γまたはCD36である、請求項6に記載のロゼブリア属菌株。
- 前記菌株は、ロゼブリア・インテスティナリス(Roseburia intestinalis)である、請求項1に記載のロゼブリア属菌株。
- 前記菌株は、寄託番号KCTC13327BPを有するロゼブリア・インテスティナリス(Roseburia intestinalis)SNUG30017である、請求項1に記載のロゼブリア属菌株。
- 請求項1〜9のいずれか一項に記載のロゼブリア属菌株、前記菌株の鞭毛抽出物、前記菌株の培養物、前記培養物の濃縮液および乾燥物からなる群より選択される1種以上を含む、アルコール性脂肪肝の予防または治療用薬学組成物。
- 請求項1〜9のいずれか一項に記載のロゼブリア属菌株、前記菌株の鞭毛抽出物、前記菌株の培養物、前記培養物の濃縮液および乾燥物からなる群より選択される1種以上を含む、アルコール性脂肪肝の予防または改善用食品組成物。
- 請求項1〜9のいずれか一項に記載のロゼブリア属菌株、前記菌株の鞭毛抽出物、前記菌株の培養物、前記培養物の濃縮液および乾燥物からなる群より選択される1種以上を含む、アルコール性脂肪肝の予防または改善用プロバイオティクス組成物。
- 前記ロゼブリア属菌株は、腸内微生物菌叢の多様性増加、または代謝と関連した腸内微生物菌叢機能性増加を誘発するものである、請求項12に記載のプロバイオティクス組成物。
- 対象の腸内に存在する、請求項1〜9のいずれか一項に記載のロゼブリア属菌株を定量する製剤を含むアルコール性脂肪肝の診断用組成物。
- 脂肪酸代謝物である酪酸およびプロピオン酸の濃度を定量する製剤を含む、請求項14に記載のアルコール性脂肪肝の診断用組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0126557 | 2017-09-28 | ||
KR20170126557 | 2017-09-28 | ||
KR10-2018-0115823 | 2018-09-28 | ||
KR1020180115823A KR102212606B1 (ko) | 2017-09-28 | 2018-09-28 | 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물 |
PCT/KR2018/011564 WO2019066577A2 (ko) | 2017-09-28 | 2018-09-28 | 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020534858A true JP2020534858A (ja) | 2020-12-03 |
JP7033655B2 JP7033655B2 (ja) | 2022-03-10 |
Family
ID=66104379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020518722A Active JP7033655B2 (ja) | 2017-09-28 | 2018-09-28 | 短鎖脂肪酸生成腸内細菌群集の変化を用いたアルコール性肝疾患の診断および治療用組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11510948B2 (ja) |
EP (1) | EP3690026A4 (ja) |
JP (1) | JP7033655B2 (ja) |
KR (1) | KR102212606B1 (ja) |
CN (1) | CN111527195B (ja) |
AU (1) | AU2018341734B2 (ja) |
CA (1) | CA3076884A1 (ja) |
WO (1) | WO2019066577A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109259146B (zh) * | 2018-08-27 | 2022-05-20 | 南昌大学 | 鼠李糖乳杆菌在制备具有抑制脂肪肝病变功效的组合物中的应用 |
CA3140096A1 (en) * | 2019-05-21 | 2020-11-26 | Pendulum Therapeutics, Inc. | Methods and compositions for treating liver disorders |
KR102363094B1 (ko) | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 간질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 간질환 예방 또는 치료제 스크리닝 방법 |
CN111733137A (zh) * | 2020-07-13 | 2020-10-02 | 江南大学 | 一种筛选可预防和/或治疗酒精性肝损伤的药物的方法 |
KR20220041406A (ko) | 2020-09-25 | 2022-04-01 | 한국식품연구원 | 장내 미생물을 이용한 간질환 개선, 예방 또는 치료용 조성물 및 그를 이용한 간질환의 치료방법 |
CN113181151A (zh) * | 2020-12-29 | 2021-07-30 | 山东善维免疫科技有限公司 | 短链脂肪酸在预防或/和治疗肝损伤中的应用 |
KR102646205B1 (ko) | 2021-02-15 | 2024-03-12 | 국립안동대학교 산학협력단 | 엘라그산을 유효성분으로 포함하는 장내 미생물 개선용 조성물 |
KR20240130121A (ko) * | 2021-12-27 | 2024-08-28 | 엠알엠 헬스 엔.브이. | 미생물 군집 |
AU2023210125A1 (en) * | 2022-01-20 | 2024-08-08 | Korea Institute Of Science And Technology | Composition for prevention, amelioration or treatment of non-alcoholic fatty liver disease, comprising extracellular vesicles derived from roseburia spp. or bifidobacterium spp. |
CN114621936B (zh) * | 2022-03-02 | 2023-10-24 | 中南大学湘雅二医院 | 蛋白组合物及其用途 |
CN114796285B (zh) * | 2022-04-29 | 2023-06-23 | 大连工业大学 | 嗜黏蛋白阿克曼氏菌在缓解高尿酸血症中的应用 |
CN114854884A (zh) * | 2022-05-27 | 2022-08-05 | 山东农业大学 | 用属水平的粪便微生物预警或无创诊断脂肪肝奶牛的方法 |
CN115804793A (zh) * | 2022-06-08 | 2023-03-17 | 广州知易生物科技有限公司 | 嗜粘蛋白阿克曼菌在制备改善酒精性肝功能异常的组合物中的应用、组合物及应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101158472B1 (ko) * | 2009-11-05 | 2012-06-20 | 주식회사 베네비오 | 알코올에 유발된 간질환의 예방 또는 치료용 조성물 |
KR101303541B1 (ko) * | 2011-06-15 | 2013-09-03 | 세명대학교 산학협력단 | 알코올성 간손상 내지 알코올성 지방간 예방 및 숙취해소 효과를 갖는 조성물 |
ES2662793T3 (es) * | 2011-09-14 | 2018-04-09 | Nubiyota Llc | Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos |
GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
WO2014159510A1 (en) | 2013-03-12 | 2014-10-02 | Yale University | Compositions and methods for identifying secretory antibody-bound microbes |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CN104413334A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
RU2017134547A (ru) | 2015-04-23 | 2019-04-09 | Калейдо Байосайенсиз, Инк. | Регуляторы микробиома и соответствующие варианты их применения |
EP3943093A1 (en) | 2015-09-10 | 2022-01-26 | Université catholique de Louvain | Use of pasteurized akkermansia for treating cancer |
KR20170032815A (ko) | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물 |
TWI589297B (zh) * | 2016-04-25 | 2017-07-01 | Use of melon leaf extract for the treatment and / or prevention of alcoholic fatty liver or its complications | |
RU2020110462A (ru) * | 2017-08-14 | 2021-09-16 | Серес Терапеутикс, Инк. | Композиции и способы для лечения холестатического заболевания |
-
2018
- 2018-09-28 WO PCT/KR2018/011564 patent/WO2019066577A2/ko unknown
- 2018-09-28 CA CA3076884A patent/CA3076884A1/en active Pending
- 2018-09-28 JP JP2020518722A patent/JP7033655B2/ja active Active
- 2018-09-28 KR KR1020180115823A patent/KR102212606B1/ko active IP Right Grant
- 2018-09-28 US US16/648,358 patent/US11510948B2/en active Active
- 2018-09-28 EP EP18860264.3A patent/EP3690026A4/en active Pending
- 2018-09-28 CN CN201880076591.7A patent/CN111527195B/zh active Active
- 2018-09-28 AU AU2018341734A patent/AU2018341734B2/en active Active
-
2022
- 2022-10-27 US US18/050,091 patent/US11903980B2/en active Active
Non-Patent Citations (2)
Title |
---|
FRONTIERS IN PHYSIOLOGY, vol. Vol. 8, Artilcle 319, JPN6021018657, 19 May 2017 (2017-05-19), pages 1 - 17, ISSN: 0004513712 * |
FUTURE MICROBIOL.(2017) 12(2), 157-170, JPN6021018659, 31 January 2017 (2017-01-31), ISSN: 0004513711 * |
Also Published As
Publication number | Publication date |
---|---|
US11903980B2 (en) | 2024-02-20 |
CA3076884A1 (en) | 2019-04-04 |
EP3690026A2 (en) | 2020-08-05 |
JP7033655B2 (ja) | 2022-03-10 |
US20230190829A1 (en) | 2023-06-22 |
CN111527195B (zh) | 2023-11-03 |
KR102212606B1 (ko) | 2021-02-05 |
AU2018341734A1 (en) | 2020-04-16 |
EP3690026A4 (en) | 2021-06-23 |
WO2019066577A2 (ko) | 2019-04-04 |
KR20190037170A (ko) | 2019-04-05 |
US20210052674A1 (en) | 2021-02-25 |
WO2019066577A3 (ko) | 2019-07-04 |
US11510948B2 (en) | 2022-11-29 |
AU2018341734B2 (en) | 2022-02-03 |
CN111527195A (zh) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7033655B2 (ja) | 短鎖脂肪酸生成腸内細菌群集の変化を用いたアルコール性肝疾患の診断および治療用組成物 | |
WO2019156251A1 (ja) | リポ多糖制御性腸内細菌及びその用途 | |
JP7360420B2 (ja) | ディスバイオシスの治療のために用いられるブドウ果皮 | |
Huang et al. | Lycium barbarum Glycopeptide prevents the development and progression of acute colitis by regulating the composition and diversity of the gut microbiota in mice | |
US20210093677A1 (en) | Nanovesicles derived from faecalibacterium prausnitzii and uses thereof | |
Tarrah et al. | Lactobacillus paracasei DTA81, a cholesterol‐lowering strain having immunomodulatory activity, reveals gut microbiota regulation capability in BALB/c mice receiving high‐fat diet | |
KR102641644B1 (ko) | 락토바실러스 플란타룸의 치료적 용도 | |
WO2023076874A1 (en) | Methods and composition for the treatment of prader-willi syndrome symptoms | |
KR102700146B1 (ko) | 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물 | |
CN112752579A (zh) | 用于促进健康的Anaerostipes hadrus | |
WO2023068279A1 (ja) | ブラウチア(Blautia)属細菌のスクリーニング方法 | |
Metras | EVALUATING TRADITIONAL AND COMMERCIAL KEFIR PRODUCTS FOR HUMANS AND COMPANION ANIMALS | |
KR20220041410A (ko) | 장내 미생물을 이용한 신질환 개선, 예방 또는 치료용 조성물 및 그를 이용한 신질환의 치료방법 | |
Park et al. | Combining 2'-fucosyllactose and galactooligosaccharides exerts anti-inflammatory effects and promotes gut health | |
KR20220041403A (ko) | 장내 미생물을 이용한 비만 개선, 예방 또는 치료용 조성물 및 그를 이용한 비만의 치료방법 | |
KR20220041406A (ko) | 장내 미생물을 이용한 간질환 개선, 예방 또는 치료용 조성물 및 그를 이용한 간질환의 치료방법 | |
KR20220041401A (ko) | 장내 미생물을 이용한 당뇨병 개선, 예방 또는 치료용 조성물 및 그를 이용한 당뇨병의 치료방법 | |
Maccaferria et al. | Potential probiotic Kluyveromyces marxianus fragilis B0399 modulates the immune response 1 in Caco-2 cells and PBMCs and impacts on the human gut microbiota in an in vitro colonic 2 model system 3 | |
Maccaferri | Characterization of novel probiotics and prebiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210825 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7033655 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |